It’s no exaggeration that calcium represents the Achilles heel of endovascular treatment. As the patient population continues to evolve in complexity we need solutions that can treat severe calcified disease in an efficacious, safe and durable way. Listen as Dr Konstantinos Stavroulakis shares the outcomes of his recent publication of Intravascular Lithotripsy (IVL) and DCB in severely calcified femoropopliteal lesions followed out to 12 months and understand why he believes IVL is a game changer in the treatment of complex real world patients.
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Clinical Data
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Read More
Topics:
Coronary IVL,
IVL Case,
Peripheral IVL,
Shockwave Breaking News,
IVL Technology,
DISRUPT PAD,
Coronary Cases,
Peripheral Cases,
PAD Applications - BTK,
Peripheral Conferences,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave M5,
Shockwave S4,
PAD Applications - TEVAR,
Coronary IVL - U.S.,
ShockwaveM5+
The presence of calcium can pose significant challenges in achieving optimal procedural outcomes in PAD treatment and can pose as a barrier to the delivery of large bore access devices. Shockwave IVL is shifting the paradigm in the way physicians approach calcium by simplifying procedures in an efficacious and safe manner. Now the next generation of peripheral IVL technology is here: Shockwave M5+! The Shockwave M5+ extends treatment options with the introduction of its new features; faster pulsing, an extended working length and expanded size matrix.
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Clinical Data
2021 was Shockwave’s best year yet! Although it brought challenges, with it came immense opportunities which allowed us to grow and exceed expectations. As we push on into 2022, we are excited for what the year will bring but most importantly, for the opportunities to continue to help improve patient outcomes across the globe. But before we get started, let’s review the highlights of last quarter. We released four data releases, including our 1-year results of our Coronary IVL pivotal study at TCT this year, making it a monumental event. We had some exciting peer-reviewed publications come out, enrolled the first patient in the Disrupt BTK II Study, and much more. Read the latest PulsePoint for all the updates!
Read More
Topics:
Coronary IVL,
IVL Case,
Peripheral IVL,
IVL Technology,
Coronary Cases,
Peripheral Cases,
Shockwave C2,
Shockwave M5,
Shockwave S4,
PulsePoint Newsletter,
Coronary IVL - U.S.
Alternative access strategies in TAVI are prone to higher complication rates when compared to transfemoral access. This leads to the question; should physicians tackle difficult transfemoral over alternative access?
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Conferences,
Peripheral Clinical Data
Great news! The Centers for Medicare and Medicaid Services (CMS) has increased payment for peripheral IVL procedures. The increases apply to procedures performed in anatomical locations above the knee in a hospital outpatient setting. The changes go into effect on January 1, 2022.
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Clinical Data
Transfemoral access represents the gold standard for TAVI, with TF access showing a significant reduction in complications and mortality in comparison to alternative access strategies, which add additional complexity and risk to the procedure. Despite the wide acceptance that the transfemoral route provides the safest access for patients, the approach can be hindered by calcified iliac arteries inhibiting delivery of large bore devices by restricting the luminal diameter and reducing vessel compliance. If calcium is not treated adequately prior to TAVI delivery, this can lead to complications such as flow limiting dissection, vessel rupture and unsuccessful delivery of the implant.
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Clinical Data
Winter is coming… and fast but before we enter the final home stretch of the year, let’s recount the milestones of the recent quarter in the latest edition of the PulsePoint Newsletter. Shockwave hit the ground running this quarter by bringing on various IVL experts from across the globe to discuss all things calcium on the ChalkTalk Podcast Series. Shockwave also made headlines in CathLab Digest with several physician-authored perspectives about the role of the technology in clinical practice. And it was great to finally get back to live, in-person conferences like VIVA ’21, where the results from the first 752 patients in the Disrupt PAD III Observational Study were presented. Catch up on what you may have missed and don’t forget watch the CalciumMasterclass.com series finale!
Read More
Topics:
Coronary IVL,
IVL Case,
Peripheral IVL,
IVL Technology,
Coronary Cases,
Peripheral Cases,
Shockwave C2,
Shockwave M5,
Shockwave S4,
PulsePoint Newsletter,
Coronary IVL - U.S.
On Thursday, November 18, join us and six IVL experts at VEITH 2021 to hear how Intravascular Lithotripsy (IVL) works across multiple vessel beds.
Read More
Topics:
Peripheral IVL,
DISRUPT PAD,
Peripheral Cases,
Peripheral Conferences,
Peripheral Clinical Data
Calcium causes a magnitude of problems in EVAR and TEVAR procedures. Calcium can inhibit stent graft delivery leading to significant dissection or perforation of the iliac arteries. Calcium can also affect expansion of iliac limbs leading to increased risk of under expansion and stent graft thrombosis.
Watch as Dr. Stefano Fazzini, Tor Vergata University Hospital, Italy walks you through how Shockwave IVL can help alleviate access challenges while minimizing complications and the need for secondary interventions.
Read More
Topics:
Peripheral IVL,
DISRUPT PAD,
Peripheral Cases,
Peripheral Conferences,
Peripheral Clinical Data
